ELITE PHARMACEUTICALS INC /NV/ (ELTP)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 03-31. Amounts in USD.

2Y 5Y 10Y All
Quarterly Annual TTM

Revenue Annual

0 60M 120M 180M FY11: 4.3M FY12: 2.4M FY13: 3.4M FY14: 4.6M FY15: 5M FY16: 12.5M FY17: 9.6M FY18: 7.5M FY19: 7.6M FY20: 18M FY21: 25.4M FY22: 32.3M FY23: 34.2M FY24: 56.6M FY25: 84M FY26: 148.9M FY12 FY14 FY16 FY18 FY20 FY22 FY24 FY26

Gross Profit Annual

0 30M 60M 90M FY11: 1.6M FY12: 1.4M FY13: 1.1M FY14: 1.4M FY15: 2M FY16: 8M FY17: 3.7M FY18: 3.9M FY19: 2.9M FY20: 8M FY21: 11.9M FY22: 14.8M FY23: 16.6M FY24: 26.4M FY25: 40.1M FY26: 75M FY12 FY14 FY16 FY18 FY20 FY22 FY24 FY26

Operating Income Annual

-20M 0 20M 40M 60M FY11: -885.8K FY12: -2M FY13: -1.6M FY14: -5.3M FY15: -16.5M FY16: -8.3M FY17: -7.4M FY18: -9.1M FY19: -9.2M FY20: -2.3M FY21: 2.1M FY22: 5.1M FY23: 3.7M FY24: 10.8M FY25: 19.6M FY26: 49.1M FY12 FY14 FY16 FY18 FY20 FY22 FY24 FY26

Net Income Annual

-60M -40M -20M 0 20M 40M 60M FY11: -13.6M FY12: -15.1M FY13: 1.5M FY14: -41.3M FY15: 5.2M FY16: -683K FY17: 3.8M FY18: -3.7M FY19: -9.3M FY20: -2.2M FY21: 5.1M FY22: 8.9M FY23: 3.6M FY24: 20.1M FY25: -4.3M FY26: 44.9M FY12 FY14 FY16 FY18 FY20 FY22 FY24 FY26

Cost of Revenue Annual

0 30M 60M 90M FY11: 2.7M FY12: 1M FY13: 2.3M FY14: 3.2M FY15: 3M FY16: 4.5M FY17: 5.9M FY18: 3.5M FY19: 4.7M FY20: 10M FY21: 13.5M FY22: 17.5M FY23: 17.6M FY24: 30.3M FY25: 44M FY26: 73.8M FY12 FY14 FY16 FY18 FY20 FY22 FY24 FY26

Operating Cash Flow Annual

-18M -9M 0 9M 18M 27M FY11: 1.6M FY12: -394.1K FY13: -1.9M FY14: -4.2M FY15: -15.1M FY16: -2.8M FY17: -7.9M FY18: -4.8M FY19: -6.8M FY20: -1.8M FY21: 3.2M FY22: 6.5M FY23: 3.3M FY24: -3.2M FY25: 7.5M FY26: 23.7M FY12 FY14 FY16 FY18 FY20 FY22 FY24 FY26

Free Cash Flow Annual

-24M -16M -8M 0 8M 16M 24M FY11: 1.4M FY12: -595.9K FY13: -2.1M FY14: -4.7M FY15: -17.1M FY16: -4.7M FY17: -9M FY18: -5M FY19: -6.8M FY20: -1.8M FY21: 2.9M FY22: 6M FY23: -2.4M FY24: -4M FY25: 5.8M FY26: 22.8M FY12 FY14 FY16 FY18 FY20 FY22 FY24 FY26

Operating cash flow minus capital expenditure.

Shares Outstanding Annual

0 400M 800M 1.2B FY12: 259.2M FY13: 526.9M FY14: 463M FY15: 757.6M FY16: 673.9M FY17: 844.5M FY18: 798.2M FY19: 816.3M FY20: 993.3M FY21: 943M FY22: 1B FY23: 1B FY24: 1B FY25: 1.1B FY26: 1.1B FY12 FY14 FY16 FY18 FY20 FY22 FY24 FY26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-0.21 -0.14 -0.07 0.00 0.07 0.14 0.21 Q4 '12: -0.06 Q1 '13: 0.04 Q2 '13: 0.01 Q3 '13: -0.01 Q4 '13: 0.00 Q1 '14: 0.03 Q2 '14: 0.01 Q3 '14: 0.01 Q4 '14: -0.18 Q1 '16: -0.03 Q2 '17: -0.05 Q3 '17: 0.00 Q4 '17: -0.01 Q1 '18: -0.01 Q2 '18: -0.01 Q3 '18: -0.01 Q4 '18: 0.00 Q1 '19: 0.00 Q2 '19: 0.00 Q3 '19: 0.00 Q4 '19: 0.00 Q1 '20: 0.00 Q2 '20: 0.00 Q3 '20: 0.00 Q4 '20: 0.00 Q1 '21: 0.00 Q2 '21: 0.00 Q3 '21: 0.00 Q4 '21: 0.00 Q1 '22: 0.00 Q2 '22: 0.00 Q3 '22: 0.00 Q4 '22: 0.01 Q1 '23: 0.01 Q2 '23: 0.01 Q3 '23: 0.01 Q4 '23: 0.00 Q1 '24: 0.00 Q2 '24: 0.01 Q3 '24: 0.01 Q4 '24: 0.01 Q1 '25: 0.01 Q2 '25: -0.01 Q3 '25: -0.02 Q4 '25: 0.00 Q1 '26: -0.01 Q2 '26: 0.01 Q3 '26: 0.03 Q4 '26: 0.02 Q1 '27: 0.04 Q4 '12 Q3 '14 Q2 '18 Q1 '20 Q4 '21 Q3 '23 Q2 '25 Q1 '27

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.